黑料吃瓜群网

Introducing bacteria to a tumour鈥檚 microenvironment creates a state of acute inflammation that triggers the immune system鈥檚 primary responder cells to attack rather than protect a tumour, according to researchers from the .

The first-responder cells, called neutrophils, are white blood cells that play an important role in defence against infection. While they generally protect against disease, they are notorious for promoting tumour growth; high levels of them in the blood are typically associated with poorer outcomes in cancer, in part because they produce molecules that shield the tumour by suppressing the other elements of the immune system.

The researchers, led by Dr Tatyana Chtanova, Head of the聽 at Garvan and Associate Professor at the School of Biotechnology and Biomolecular Sciences at UNSW Sydney, found that injecting inactivated Staphylococcus aureus microbes inside a tumour reverses that protective activity, stimulating the neutrophils to destroy the tumour in a range of animal cancer models, including Lewis lung carcinoma, triple-negative breast cancer, melanoma and pancreatic cancer.

鈥淯sing the immune system to fight cancer has been one of the biggest breakthroughs in cancer therapy in the last two decades, but currently immunotherapy for improving T cell function doesn鈥檛 work for all types of cancer.

鈥淲e decided to use a different type of immunotherapy that targets neutrophils, to understand how generating acute inflammation in the immunosuppressive tumour microenvironment affects outcomes,鈥� Chtanova said.

The team used intravital imaging in animal studies to see inside the tumours in real time.

鈥淪ince attacking bacteria is the reason for neutrophils鈥� existence, we had a good inkling that introducing bacteria would bring neutrophils to the site and activate them. We discovered that it鈥檚 very effective in getting them to kill the tumours, chewing up their matrix,鈥� she said.

The study, published in the journal , shows that the neutrophils also change at the gene expression level: they begin to secrete molecules that will attract fighter T cells as reinforcement.

鈥淲e鈥檝e shown that microbial therapy is an effective booster for checkpoint inhibitor therapy, another type of cancer immunotherapy. We hope this synergistic effect will ultimately lead to better treatments to improve outcomes for patients with advanced or previously untreatable cancers,鈥� said first author of the study Dr Andrew Yam, clinical medical oncologist at The Kinghorn Cancer Centre and PhD student at Garvan.

The study focused on primary tumours. Over the next three to five years, the team hope to develop the therapy to fight metastasis, the spread of cancer to other areas of the body, with clinical trials to follow.

Image credit: iStock.com/wildpixel